Positions Before the Calendar: CXO at a 10.3% Fund Weighting, With Three Policy Dates Inside 60 Days

Mutual fund Q3 2026 filings are in: healthcare fund weighting in pharma rose to 10.3% (+3.6 points quarter-on-quarter), and medical R&D outsourcing was the standout — up 7.14 points in pharma funds and 11.75 points in non-pharma funds, the largest increase of any subsector, with WuXi AppTec ranking first on both value and fund count in both cohorts. Yet the sector's PE percentile has fallen from above 70% in September to about 45%, and guidance upgrades have not stuck in the share price. Positions and policy are now racing: 15 November, 7 December and 18 December will decide whether this crowded trade is confirmed.

Q3 2026 fund filings are complete, and pharma was the single most-added sector for Chinese mutual funds. Data show the healthcare fund weighting in pharma rose to 10.3%, up 3.6 percentage points quarter-on-quarter; medical R&D outsourcing (CXO) surged within that — up 7.14 points among pharma funds and 11.75 points among non-pharma funds, the largest increase of any pharmaceutical subsector.

At the single-stock level, WuXi AppTec ranked first on both heavy-positioning value and fund count among both pharma and non-pharma funds, with Pharmaron and Asymchem clearly added. An earlier tally put WuXi AppTec's single-quarter fund buying at roughly 20.2 billion yuan, WuXi Biologics at 7.3 billion and GenScript Biotech at 4.8 billion. The migration of capital from Biotech toward CXOs with earnings visibility is the defining move of this repositioning.

The depth of the rotation shows in finer cuts: Tianfeng Securities counts the CDMO overweight within active pharma funds rising from 8.1% to 12.9%; Huafu Securities measures active pharma funds' CXO allocation at 34.3%, up 10.9 points, while Bio-Pharma, Pharma and Bio-Tech allocations all fell. Nearly all of the top gainers in heavy-positioning value sat in outsourcing and research-services: WuXi AppTec 11.56 billion yuan (up 2.58 billion), Pharmaron 6.60 billion (up 3.33 billion), Asymchem 6.34 billion (up 0.63 billion), Tigermed 3.93 billion (up 2.18 billion).

Why CXO

Institutions give three reasons. First, fundamentals: the Q3 reports confirmed the shift from order recovery to profit delivery — WuXi AppTec's backlog reached 76.74 billion yuan and full-year guidance was raised twice to 61.0-61.9 billion, as we traced in our gradient-recovery piece. Second, financing: global biotech funding improved and Chinese out-licensing accelerated — 100 deals worth roughly 99.7 billion dollars in the first half of 2026, about twice the full-year 2024 total. Third, valuation: the sector's PE percentile fell from above 70% in September to about 45%, reopening repair room. Harvest Fund's Hao Miao put it plainly: 2026 is the first year of domestic-and-overseas demand resonance for CXO, with a visible 2-3 year earnings upcycle.

Notably, the buyers were not only pharma funds. Managers previously concentrated in technology began adding healthcare in Q3 — one fund moved from an all-AI top ten to naming WuXi AppTec as its largest holding. Cross-industry migration of this kind usually says more than internal reshuffling: with earnings season closed and high-technology de-levering, CXO — low, delivering, order-visible — was the natural landing spot for the great rotation.

But the price has not followed: where the disagreement sits

Share prices diverge from the positioning heat. In the final week of October the pharma index fell 2.17% (outperforming the CSI 300 by about 0.75 points) and CXO slipped just 0.51% — better than most subsectors but not positive — and early November brought broad pullbacks among leaders. Guidance upgrades have not stuck in the tape: the market is using a PE percentile of roughly 45% to bargain over a set of policy variables that have not yet landed.

That calendar is explicit. First date: 15 November — the comment deadline for MOFCOM and MOST's Announcement No. 48 draft export-control catalogue additions (five biopharma entries touching CGT and small-nucleic-acid process platforms; out-licensing and CRO/CDMO services for hire are in principle outside the prohibited or restricted scope, as we examined in October). Second: 7 December — the comment deadline for the US Treasury's COINS Act proposed rule, which places biotechnology in the prohibited category for outbound investment while exempting cash-for-licence deals and equity-free service procurement. Third, and heaviest: 18 December — the statutory deadline for OMB's first list of Biotechnology Companies of Concern under the BIOSECURE mechanism; WuXi AppTec's US revenue share was 77.1% in the first half of 2026, making this the widest-tailed variable of the three.

Three scripts for the next 60 days

For holders, the coming two months map to three scripts. The benign case: all three dates come with buffers — the final Chinese catalogue preserves the outsourcing exemption, the COINS final rule narrows the drug-equipment scope per industry comments, and the BCC list slips or omits the WuXi system — in which case a 10.3% weighting gets confirmed by both fundamentals and policy, and valuation repairs upward from the 45th percentile. The stress case: any node tightens beyond expectation, and crowding amplifies the drawdown — the more concentrated the positions, the sharper the calendar-driven volatility. The middle case is most likely: a name on a list, a clause tightened, but the commercial perimeter still confined to federal procurement and federal funding — largely priced already, with 2027 order data deciding the direction.

Huayuan Securities' phrasing is that CXO has entered a stock-picker's phase after the correction. Translated into portfolio language: the beta has been bought; what remains is pricing each policy node. The Q3 filings pushed the chips to the front row. For the next 60 days, the calendar gets to speak.